SMAD3 hypomethylation as a biomarker for early prediction of colorectal cancer

Muhamad Ansar, Chun Jung Wang, Yu Han Wang, Tsung Hua Shen, Chin Sheng Hung, Shih Ching Chang*, Ruo Kai Lin


研究成果: Article同行評審

5 引文 斯高帕斯(Scopus)


The incidence and mortality rates of colorectal cancer (CRC) have been high in recent years. Prevention and early detection are crucial for decreasing the death rate. Therefore, this study aims to characterize the alteration patterns of mothers against decapentaplegic homolog 3 (SMAD3) in patients with CRC and its applications in early detection by using a genome-wide methylation array to identify an aberrant hypomethylation site in the intron position of the SMAD3 gene. Quantitative methylation-specific polymerase chain reaction showed that hypomethylated SMAD3 occurred in 91.4% (501/548) of Taiwanese CRC tissues and 66.6% of benign tubular adenoma polyps. In addition, SMAD3 hypomethylation was observed in 94.7% of patients with CRC from The Cancer Genome Atlas dataset. A decrease in circulating cell-free methylation SMAD3 was detected in 70% of CRC patients but in only 20% of healthy individuals. SMAD3 mRNA expression was low in 42.9% of Taiwanese CRC tumor tissues but high in 29.4% of tumors compared with paired adjacent normal tissues. Hypomethylated SMAD3 was found in cancers of the digestive system, such as liver cancer, gastric cancer, and colorectal cancer, but not in breast cancer, endometrial cancer, and lung cancer. In conclusion, SMAD3 hypomethylation is a potential diagnostic marker for CRC in Western and Asian populations.

頁(從 - 到)1-19
期刊International Journal Of Molecular Sciences
出版狀態Published - 1 10月 2020


深入研究「SMAD3 hypomethylation as a biomarker for early prediction of colorectal cancer」主題。共同形成了獨特的指紋。